Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
One innovative solution that's gaining traction is the use of BPC-157/TB-500 nasal spray
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by AASLD and EASL
Multiple studies have found many adults with CKD or at risk for CKD do not have urinary albumin-to-creatine ratio (UACR), a key biomarker for CKD, measured on an annual basis
You expect a real person on chat or email support
Revlimid (lenalidomide) Disease area(s): Oncology/hematology Manufacturer(s): Bristol Myers Squibb 2024 Sales (USD): $5.77 billion Why it sold so well: In 2024, BMS Revlimid generated $5.77 billion in global revenue, maintaining its position as one of the companys top-selling products despite facing generic competition
US$ 27.59
US$ 22.36
US$ 24.09
US$ 26.59
